Look back at pharma news to Oct 27

Last week’s news was largely dominated by financial results, with among many others, Swiss pharma giant Novartis pleasing investors, while Celgene and Gilead Sciences disappointed. Also attracting a good deal of attention was MacroGenics lucrative deal with Incyte for cancer drug candidate MGA012, and Novartis gaining breakthrough status for its melanoma drug combination Tafinlar+Mekinist.

Novartis 3rd-qtr: strong signals but wait for better entry point

On October 24, Novartis reported better-than-expected  third-quarter 2017 results fueled by a solid performance from the key growth drivers in the Pharmaceutical Division and some encouraging profitability improvement for Alcon and Sandoz, commented “Health Blogger” on Seeking Alpha.